Below are the most recent publications written about "CD4-Positive T-Lymphocytes" by people in Profiles.
-
Li R, Daneshvar K, Ji X, Pleet M, Igbinosun G, Iqbal MS, Kashanchi F, Mullen AC, Romerio F. Suppression of HIV-1 transcription and latency reversal via ectopic expression of the viral antisense transcript AST. Sci Adv. 2025 May 09; 11(19):eadu8014.
-
Olety B, Usami Y, Peters P, Wu Y, G?ttlinger H. The ectodomain sheddase ADAM10 restricts HIV-1 propagation and is counteracted by Nef. Sci Adv. 2025 Apr 18; 11(16):eadt1836.
-
Proulx MK, Wiggins CD, Reames CJ, Wu C, Kiritsy MC, Xu P, Gallant JC, Grace PS, Fenderson BA, Smith CM, Lindestam Arlehamn CS, Alter G, Lauffenburger DA, Sassetti CM. Noncanonical T cell responses are associated with protection from tuberculosis in mice and humans. J Exp Med. 2025 Jul 07; 222(7).
-
Almeida GG, Costa CM, Costa PAC, Gomes GR, Figueiredo MM, Torres KJ, de Carvalho AF, Valiate BVS, Sampaio JR, Carvalho BC, Pereira DB, Martines A, Tada MS, Soares IS, Ponmattam J, Castro MC, Golenbock DT, Gazzinelli RT, Antonelli LRDV. Asymptomatic vivax malaria is associated with an IFN-?-program on adaptive immunity. J Transl Med. 2025 Mar 19; 23(1):351.
-
Chang E, Cavallo K, Behar SM. CD4 T cell dysfunction is associated with bacterial recrudescence during chronic tuberculosis. Nat Commun. 2025 Mar 17; 16(1):2636.
-
Henriques PM, Almeida GG, Rimkute I, Dos Santos LI, Liechti T, Marino AP, do Vale INPC, Vasconcelos-Santos DV, Martins-Filho OA, Gazzinelli RT, Roederer M, Sher A, Teixeira-Carvalho A, Jankovic D, Antonelli LRDV. Cytotoxic Signature and IFN-? Production Dominate CD4+ T-Cell Response During Human Toxoplasmosis. Immunology. 2025 Jun; 175(2):151-164.
-
Ravi VR, Korkmaz FT, De Ana CL, Lu L, Shao FZ, Odom CV, Barker KA, Ramanujan A, Niszczak EN, Goltry WN, Martin IMC, Ha CT, Quinton LJ, Jones MR, Fine A, Welch JD, Chen F, Belkina AC, Mizgerd JP, Shenoy AT. Lung CD4+ resident memory T?cells use airway secretory cells to stimulate and regulate onset of allergic airway neutrophilic disease. Cell Rep. 2025 Mar 25; 44(3):115294.
-
Perica K, Jain N, Scordo M, Patel R, Eren OC, Patel U, Gundem G, Domenico D, Mitra S, Socci ND, Everett JK, Roche AM, Petrichenko A, Shah GL, Arcila ME, Borsu L, Park JH, Horwitz SM, Giralt SA, Dogan A, Leslie C, Papaemmanuil E, Bushman FD, Usmani SZ, Sadelain M, Mailankody S. CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53. N Engl J Med. 2025 Feb 06; 392(6):577-583.
-
Lilie T, Bouzy J, Asundi A, Taylor J, Roche S, Olson A, Coxen K, Corry H, Jordan H, Clayton K, Lin N, Tsibris A. HIV-1 latency reversal agent boosting is not limited by opioid use. JCI Insight. 2024 Nov 22; 9(22).
-
Marchitto L, Richard J, Pr?vost J, Tauzin A, Yang D, Chiu T-J, Chen H-C, D?az-Salinas MA, Nayrac M, Benlarbi M, Beaudoin-Bussi?res G, Anand SP, Dionne K, B?langer ?, Chatterjee D, Medjahed H, Bourassa C, Tolbert WD, Hahn BH, Munro JB, Pazgier M, Smith AB, Finzi A. The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity. J Virol. 2024 Oct 22; 98(10):e0101624.